|

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

RECRUITINGSponsored by University Hospital, Rouen
Actively Recruiting
SponsorUniversity Hospital, Rouen
Started2025-10-07
Est. completion2026-10-02
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06559033

Summary

No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
* Membership of a social security scheme
* Adult having read and understood the information letter and signed the consent form

Exclusion Criteria:

* Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship

Conditions3

CancerMonoclonal Gammopathy of Undetermined SignificanceMyeloma, Multiple

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.